| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating | 
|---|
 
																	BTIG analyst Mark Massaro maintains Personalis (NASDAQ:PSNL) with a Buy and raises the price target from $6 to $11.
 
																	Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...
 
																	 
																	HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Personalis (NASDAQ:PSNL) with a Buy and maintains $8.5 pri...
 
																	Personalis, Inc. (NASDAQ:PSNL), a leader in advanced genomics for precision oncology, announced new data from an AstraZeneca ph...
 
																	 
																	
 
																	HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Personalis (NASDAQ:PSNL) with a Buy and lowers the price ta...
